[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_NewBusinessRelationAbstract|
New Business Relation
oda_UpdateAnnouncementFlag|
Update Notification Flag
Hayır (No)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
-
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_NatureOfTheOtherPartyWithWhichNewBusinessRelationWillStart|
Nature Of The Other Party With Which New Business Relation Will Start
Müşteri (Customer)
oda_NameSurnameOrCompanyTitleOfCustomerOrSupplier|
Name Surname Or Company Title Of Customer Or Supplier
Onko İlaç Sanayi ve Ticaret A.Ş.
oda_IfExistsShareOfCustomerOrSupplierInNetSalesOrCostOfGoodsSoldOnLatestDisclosedProfitOrLossAndOtherComprehensiveIncomeStatementOfCompany|
If Exists Share Of Customer Or Supplier In Net Sales Or Cost Of Goods Sold On Latest Disclosed Profit Or Loss And Other Comprehensive Income Statement Of Company
-
oda_IfExistsShareOfCustomerOrSupplierInTradeReceivablesOrDebtsOnLatestDisclosedStatementofFinancialPositionOfCompany|
If Exists Share Of Customer Or Supplier In Trade Receivables Or Debts On Latest Disclosed Statement of Financial Position Of Company
-
oda_ExpectedStartingDateOfNewBusinessRelation|
Expected Starting Date O fNew Business Relation
01/01/2022
oda_IfExistSignificantProvisionsOfTheContractTextBlock|
If Exist Significant Provisions Of The Contract
Detailed Below
oda_ImpactOfNewBusinessRelationOnCompanyActivities|
Impact Of New Business Relation On Company Activities
It will have positive impact.
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

-Unofficial Translation-

An agreement between our Company Gen İlaç ve Sağlık Ürünleri A.Ş. ("Gen") and Onko İlaç Sanayi ve Ticaret A.Ş. ("Onko İlaç") has been signed on 15.02.2021, about sale of a medicine named "Genivig" which used for treatment of neurological haematological diseases and imported by our Company to the pharmacies all over Turkey through Onko İlaç.

Sales and distribution rights granted to Onko İlaç with the agreement do not cover tender sales and sale to private hospitals, only covers sales and distribution to pharmacies.

In the Agreement, it is set forth that the amount of medicine to be supplied to Onko İlaç in 2022 will be determined separately. In order to determine amount of medicine that will be suppied to Onko İlaç in 2022, an additional agreement ("Additional Agreement") has been signed between our Company and Onko İlaç on 18.11.2021. According to the Additional Agreement, it is decided that 50.000 boxes medicine will be sold to Onko İlaç in 2022. When the total product price to be sold to Onko İlaç according to the Additional Agreement is calculated over the current TİTCK(Turkish Medicine and Medical Devices Agency) sales price, it corresponds to a gross TL 225.000.000.

With the Additional Agreement, our company's national distribution network for the medicine named "Genivig" will expand, and at the same time, the access of patients using this medicine will be facilitated.